Dyax Corp. (NASDAQ:DYAX) today announced results from a preclinical study of DX-2930, their internally developed, fully human monoclonal antibody inhibitor of plasma kallikrein, at the 2013 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting which is taking place February 22-26, 2013 in San Antonio, TX.
The poster, titled “Discovery and characterization of a fully human monoclonal antibody inhibitor of plasma kallikrein for the treatment of plasma kallikrein-mediated edema,” (poster #116) highlighted results of preclinical work that was designed to evaluate the activity of DX-2930 as a long-acting inhibitor of plasma kallikrein (pKal). Dyax currently markets KALBITOR ® (ecallantide), a specific pKal inhibitor, for treatment of acute hereditary angioedema (HAE) attacks in patients 16 years of age and older. The Company is exploring DX-2930 as a subcutaneous, long-acting, prophylactic treatment for HAE.
Data demonstrate that DX-2930 is a potent antibody inhibitor of pKal (Ki=0.14 nM) that does not bind prekallikrein or any other serine protease tested. In a preclinical model, DX-2930 reduced carrageenan-induced edema. Pharmacokinetic properties following subcutaneous injection indicate that the antibody is bioavailable (66%) and has a half-life of 12.5 days in non-human primates.
“These data are significant because they indicate that DX-2930 is a potent, highly specific, potentially long-acting antibody inhibitor of plasma kallikrein,” said Burt Adelman M.D., Chief Medical Officer and Executive Vice President at Dyax. “DX-2930 may be a viable prophylactic treatment option for hereditary angioedema and other plasma kallikrein-mediated (PKM) diseases. Our focus is on plasma kallikrein inhibition because we think it is the most logical strategy to both treat and prevent HAE attacks.”Gustav Christensen, President and CEO of Dyax added: “The findings presented today represent an important step for Dyax as we move toward our goal of expanding our angioedema portfolio to offer a preventative treatment option for those suffering from HAE and other PKM diseases.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts